Kwality Pharmaceuticals Limited Stock

Equities

KPL6

INE552U01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:19:01 2024-04-26 EDT 5-day change 1st Jan Change
507 INR +1.36% Intraday chart for Kwality Pharmaceuticals Limited +13.03% +26.81%

Financials

Sales 2022 4.58B 54.92M 75.08M Sales 2023 2.51B 30.11M 41.16M Capitalization 3.19B 38.28M 52.33M
Net income 2022 1.2B 14.39M 19.68M Net income 2023 194M 2.33M 3.18M EV / Sales 2022 1.4 x
Net Debt 2022 411M 4.92M 6.73M Net Debt 2023 829M 9.94M 13.59M EV / Sales 2023 1.6 x
P/E ratio 2022
5.02 x
P/E ratio 2023
16.5 x
Employees 579
Yield 2022 *
-
Yield 2023
-
Free-Float 24.01%
More Fundamentals * Assessed data
Dynamic Chart
Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Kwality Pharmaceuticals Limited Provides Update on Resumption of Operations At Amritsar CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Kwality Pharmaceuticals Discloses Completion of EU GMP Inspection at Himachal Pradesh, India Unit MT
Kwality Pharmaceuticals Limited Receives ANVISA Approval for Cephalosporin Plant (Unit -II) CI
Kwality Pharmaceuticals Limited Announces Change in Directorate CI
Kwality Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bulgarian Drug Agency to Conduct Audit on Kwality Pharmaceuticals' Plant in Himachal Pradesh, India MT
Kwality Pharmaceuticals to Bring Oncology Injection in Brazil MT
Kwality Pharmaceuticals to Market Oncology Injection in Brazil MT
Kwality Pharmaceuticals Received ANVISA Approval For Oncology Injection CI
Kwality Pharmaceuticals Receives ANVISA Approval For Oncology Injection CI
Kwality Pharmaceuticals Limited Announces the Resignation of Sachin Seth as Non- Executive and Non Independent Director CI
More news
1 day+1.36%
1 week+13.03%
Current month+23.84%
1 month+20.06%
3 months+14.41%
6 months+47.19%
Current year+26.81%
More quotes
1 week
448.00
Extreme 448
525.20
1 month
414.00
Extreme 414
525.20
Current year
385.00
Extreme 385
545.00
1 year
248.00
Extreme 248
545.00
3 years
82.10
Extreme 82.1
1 117.00
5 years
21.30
Extreme 21.3
1 117.00
10 years
20.43
Extreme 20.425
1 117.00
More quotes
Managers TitleAgeSince
Founder 69 83-05-03
Director of Finance/CFO 30 15-10-21
Compliance Officer - 19-07-22
Members of the board TitleAgeSince
Founder 69 83-05-03
Director/Board Member 56 -
Director of Finance/CFO 30 15-10-21
More insiders
Date Price Change Volume
24-04-26 507 +1.36% 19,777
24-04-25 500.2 -1.43% 8,323
24-04-24 507.4 +2.63% 29,254
24-04-23 494.4 +4.99% 5,519
24-04-22 471 +4.99% 7,778

Delayed Quote Bombay S.E., April 26, 2024 at 06:19 am

More quotes
Kwality Pharmaceuticals Limited is a manufacturer of finished pharmaceutical formulations in a dosage form. The Company is engaged in the business of manufacturers, buyers, and sellers of and dealers in all kinds of drug intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages, and other medical preparations. It manufactures exports pharmaceutical formulations in liquid orals, powder for oral suspension, tablets, capsules, sterile powder for injections, small volume injectables, ointments, external preparations, oral rehydration solutions (ORS), and others in various categories like beta lactam and non-beta lactam, hormones, cytotoxic (oncology) and effervescent. The Company specializes in handling customized business as per the requirements. The Company has about 48 different sections available at their production centers. The Company has registered its products in different countries of Europe, Africa, Asia, and others.
More about the company